<i>In vitro</i> transport of gimatecan (7-<i>t</i>-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2
Serena Marchetti, Jan H.M. Schellens(Utrecht University), Roos L. Oostendorp(Medical Genetics Center), Olaf van Tellingen(Dutch Cancer Society), Alfred H. Schinkel(Oncode Institute), Jos H. Beijnen(The Netherlands Cancer Institute), Richard Versace(Novartis (United States)), Roberto Mazzanti(Azienda Ospedaliero-Universitaria Careggi), Monique van Eijndhoven(Amsterdam UMC Location Vrije Universiteit Amsterdam), Dick Pluim
Cited by 35
Related Papers
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884